From Synchroneuron Nets $20M to Combat Drug-Induced Movement Disorder:

William Kerns

William Kerns—

William Kerns is the CEO of Waltham, MA-based Synchroneuron

Underwriters and Partners

Xconomy Insight

Sponsored · Video
Fish & Richardson: Patent Law in Regards to AI and Machine Learning
A Fireside Chat with Fish & Richardson Principal Teresa Lavoie
Fish & Richardson

Sponsored · Whitepaper
How Big Is the US Market for Medical Devices & Technologies?
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
IBM Watson

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Xconomy on Demand

We offer a number of ways to subscribe for free!